THE TAPE
QDEL · Diagnostics · $700.2M

QuidelOrtho Corporation Common Stock

$10.21▼ −4.93%
Last close
Relative strength
9RS
of 99, against every stock▼ -2 on the month
Falling back
Caution
−6.0%
six months against the S&P 500
52-week range
−71.3%
from the high
$9.92$35.58
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
Growth WEAKProof PENDING
Quarter to Sep 27, revenue −12% on a year ago
Why it is on no screen

QDEL is off the screens on 3 checks.

A base has formed13.0 weeks, from 19.50 to 32.81.
Long enough to count13.0 weeks against 3 needed.
Shallow enough40.6% deep against 35% allowed.
Close to its pivot-68.9% from the pivot; listed down to -20%.
Relative strengthRS 9 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance
Support below
None within the last 120 sessions
Resistance above
$10.32
+1.1% · tested 5× · last 5 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

QuidelOrtho Corporation Common Stock is not on any of the screens right now. Its relative strength rating is 9, and it sits in Diagnostics.

Against its industry
CautionBehind its industry over all three, in an industry that is not ahead of the S&P 500.
One month against the S&P 500
-18.4%
Three months against the S&P 500
-21.1%
Six months against the S&P 500
-6.0%

Its industry has too few members to make an index of, so it is read against the S&P 500 and can only be turning, caution or unconfirmed.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 16.0% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$2.6B
-11.6% year on year
Operating margin
-4.9%
Net margin
-14.2%
Free cash flow
$-117.1M
-16.7% of market cap
Price to sales
0.27×
Price to earnings
—
not meaningful on a loss

Twelve months to Sep 27, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 3
Key takeaway
Shrinking and burning cash: the quarter weakens the case.
Revenue
$618.9M
-1.9% QoQ · -11.6% YoY
Gross margin
—
Net income
−$53.8M
Loss
Free cash flow
−$1.4M
Burning

What the numbers say

  • Weak: Revenue -11.6% year over year, -1.9% on the quarter
  • Weak: Net loss $54M, narrower than $93M last quarter
  • Weak: Burning cash: operating cash flow $20M, free cash flow -$1M, better than -$136M last quarter
  • Weak: Growth externally funded: capex $21M against operating cash flow $20M
  • Weak: Net debt $2.77B · cash $166M
Revenue by quarter
Free cash flow
Net income
shares +1.0% in a year · net debt $2.8B

What is not obvious

  • Weak: Stock compensation $12M added back, 61% of operating cash flow; $8M after it
  • Weak: Interest $55M a quarter against an operating loss: the debt is carried by the balance sheet, not operations
Final read
Growth: WEAK · Economic proof: PENDING
Key question: What turns the cash flow positive?
The next test is revenue growth: revenue -11.6% year over year, -1.9% on the quarter.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 1 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 trimmed.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
GappedTape · 2026-11-13
-10.8%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Closed below its 20- and 50-day on heavy volumeTape · 2026-11-10
below 20d & 50d on 1.6x volume at 12.09
No measurable effect: stocks behave like random ones over the next three sessions (1,780 cases over 60 nights).
GappedTape · 2026-11-10
+13.0%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-07
-16.7%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-06
-10.5%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
A director or officer changedFiling · 2026-11-04
2.02,5.02
No measurable effect: stocks behave like random ones over the next three sessions (1,288 cases over 54 nights).
Closed above its 20- and 50-day on heavy volumeTape · 2026-11-04
above 20d & 50d on 1.7x volume at 14.09
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
GappedTape · 2026-11-03
+5.9%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
QuidelOrtho (QDEL) Beats Q3 Earnings and Revenue EstimatesZacks Investment Research · 2026-11-03Reasons to Add QuidelOrtho Stock to Your Portfolio for NowZacks Investment Research · 2026-10-14

Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.

Insiders

No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.

What analysts expect
Strong buy0
Buy1
Hold1
Sell0
Strong sell1

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
QuidelOrtho Corporation Common Stock (QDEL) — The Tape